All In Biotech

Drug Trial Radar · NCT01672047

Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients

Last checked: Nov 20, 2026Latest source record: Aug 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

350

Planned (sponsor's estimate)

Start

Apr 2012

Primary completion

Apr 2014

Study completion Dec 2015

Sponsor

Lead sponsor
Peking University People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators hypothesize that the chronic kidney disease patients who suffer from vitamin D deficiency will be benefit from given Vitamin D2 because coronary artery calcification and hyperparathyroidism will be improved.

Conditions

  • Chronic Kidney Disease
  • Vitamin D Deficiency

Interventions

  • Vitamin D2Drug

    25(OH)D level \<12 nmol/L 50000IU/weekX12week, 12-39 nmol/L 50000IU/weekX4week then,50000IU/month, 40-75 nmol/L 50000IU/month, 75-116.75nmol/L 25000IU/month, \>116.75nmol/L stopped.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the improvement of coronary artery calcificationTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The People's Hospital of Peking University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.